

on 0590

Docket No. CEN-248

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David M. Knight, et al.

Serial No.: 09/920,262

Art Unit: Not Assigned

Filed

: August 1, 2001

Examiner: Not Assigned

For

: ANTI-IL-12 ANTIBODIES, COMPOSITIONS, METHODS AND

USES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on

(Date of Deposit)

Guy Kevin Townsend (Name of applicant, assignee, or Registered Representative)

Ank 20

/0-/4-02 (Date of Signature)

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §81.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered. $% \begin{center} \begin$

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with $\S1.97(b)$, since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under $\S1.53(d)$), within three months of the date of entry into the national stage of the above identified application as set forth in $\S1.491$, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under $\S1.114$, no additional fee is required.

In accordance with $\S1.129(a)$, this Information

the
first or _second After Final Submission, therefore:
Statement in Accordance with $\S1.97(e)$
(attached); or
Please charge Deposit Account No. 10-0750/
the fee of $$180.00$ as set forth in $$1.17(p)$.
In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in \$1.97(b) above but before the
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or an

action that otherwise closes prosecution and that it is

accompanied by one of:

Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-0750/
the fee of $$180.00$ as set forth in $$1.17(p)$
☐ In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement is
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).
$oxed{\boxtimes}$ Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PT 1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references
[list as appropriate], and the likelihood that
these references are available to the Examiner
copies are not enclosed herewith.
☐ If any of the foregoing publications are not
available to the Examiner, Applicant will
endeavor to supply copies at the Examiner's
request.
igties There are no listed references which are not in the

English language.

The relevance of those listed references which are
not in the English language is as follows:
Attached are copies of search report(s) from
corresponding patent application(s), which are listed on the
attached Submission Under MPEP 609 D.
Attached are the following non-published pending
patent applications which may be deemed relevant, which are
listed on the attached Submission Under MPEP 609 D.
Please charge any deficiency or credit any overpayment to
Deposit Account No. 10-0750/CEN-248/GKT. This form is
submitted in triplicate.
Respectfully submitted,
Ank 2
Guy Kevin Townsend
Reg. No. 34,033

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003

(732) 524-2517 DATED: /0-/4-02

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to responsibilities for form 1449A/PTO nd to a collection of information unless it displays a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 2

Application Number 09/920,262 Filing Date August 1, 2001 First Named Inventor David M. Knight Group Art Unit Not Assigned Examiner Name Not Assigned Attorney Docket Number **CEN-248**

		IIIC Detect O		U.S. PATENT DOCUMENTS	A TOWN THE PARTY OF	
Examiner Initials		U.S. Patent Document				
	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passage or relevant figures appea
	-					
	- 1					
	-+					

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.1	Foreign	Patent Docu	ment		Date of Publication	Pages, Columns, Lines,	T
		Office ³	Number ⁴ KindCode ⁶		Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear	Τ°
		wo	97 15327	A	US HEALTH	05-01-1997		\vdash
		wo	96 33735	A	CELL GENESYS INC	10-31-1996		-
		wo	99 37682	Α	HOFFMANN LA ROCHE	07-29-1999		-
		wo	00 56772	A	BASF AG	09-28-2000		-
				+				
-	==			-				

Evamine

Signature Considered EXAMINER: Initial if reference considered, whether or not clasion is in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number: 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter 1 Unique cratism ossignation number: 2 see auscried Ninds of U.S. Hatent Documents, 3 Enter Unice that issued the document, by the two-terms code (MPO Standard ST.3.) 4 For Japanese patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patient document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, eApplicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any office, Washington, DC 20231.

Office, Washington, DC 20231. Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a consecuti of information unless it displays	a valid OMB control number.
Application Number	09/920,262
Filing Date	August 1, 2001
First Named Inventor	David M. Knight
Group Art Unit	Not Assigned
Attorney Docket Number	CEN-248
Examiner Name Attorney Docket Number	Not Assigned

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
Examiner's Initials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	Т
		NIKHIL, YWALKAR ET AL. "Expression of interleukin-12 is increased in psoriatic skin," Journal of Investigative Dermatology, December 1998, pages 1053-1057; Vol. 111, no. 6; XP00800577; ISSN: 0022-202X, abstract	
			Ξ
	=		_
			=
			_
	=		_
	=		_
	\equiv		
==	#		
	-		-

Gunnian		
Examiner Signature	Date	
	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Tademark Office. Washington, Oc 2021.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 2021.



SUBMISSION UNDER MPEP 609 D

Page 1 of 1

 Application Number
 09/920,262

 Filing Date
 August 1, 2001

 First Named Inventor
 David M. Knight

 Group Art Unit
 Not Assigned

 Examiner Name
 Not Assigned

		Page 1 of 1			Docket N	umber	CEN-248	
	-	U	J.S. PATE	NT DOCUMENT	S			
Examine		Name of Patentee or Applic	U.S. Patent Document					
Initials	No.	-101.10	ant			(if known)	Pages, Colu where relevan relevant figu	t passages
	-							
						+-+		
	-					E		
						-		
	+							
						+		
	-	FORE	IGN PAT	ENT DOCUMEN	TS			
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Office	eign Patent Document De Number KindCode		Pages, Columns, Line where relevant passag or relevant figures appear		T [©]
			+-					
			+-	-				
			-					
	_	OTUE PRICE						
. 1	-	OTHER PRIOR ART - Include name of the author (in title of the item (book, magazin						
xaminer itials*	Cite No.1	volume-issue number	(s), publis	sher, city and/or o	ountry whe	ie (when ap i, etc.), date re publishei	propriate), s, page(s), d	T ²
	-	PCT International Search Report PCT	/US01/247	20 dated 07-30-20	02			
								_
aminer nature			-	Date Considered				